

PATENT
674525-2002**REMARKS**

Claims 2, 4-13, 17, 19, 20, 25, 27, 30 and 32 are pending in this application and are currently amended. Claims 1, 3, 14-16, 18, 21-24, 26, 28, 29, 31, 33 and 34 are cancelled without prejudice. Support for the amendments is found throughout the specification. Specific support for "regulatory lymphocyte" can be found, for example, on page 4, line 6, of the application, and the production of regulatory cells is discussed in the section of the specification beginning on page 17, line 6. No new matter is added.

The claims, herewith and as originally filed, are patentably distinct over the prior art, and these claims are in full compliance with the requirements of 35 U.S.C. §112. The amendments and additions to the claims, as presented herein, are not made for purposes of patentability within the meaning of 35 U.S.C. §§§§ 101, 102, 103 or 112. Rather, these amendments and additions are made simply for clarification and to round out the scope of protection to which Applicants are entitled.


The Office Communication indicates that Applicants must elect either a method for producing a lymphocyte or a method for producing an antigen presenting cell (APC). In the Response filed on May 9, 2003, Applicants elected a method for producing a lymphocyte (*i.e.* the first occurrence of a cell type in each of claims 1 and 19, for example). Applicants hereby reiterate their election of a method for producing a lymphocyte. In addition, the claims have been amended to clarify the processes being claimed and the cell types involved in the processes.

Applicants further reiterate their traverse of the requirements for restriction and election, for the reasons stated in the Response filed on May 9, 2003.

In view of the foregoing, reconsideration and withdrawal of the restriction requirement and favorable examination of the pending claims on the merits are respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By: 

Thomas J. Kowalski

Reg. No. 32,147

Anne-Marie C. Yvon, Ph.D.

Reg. No. 52,390

Tel (212) 588-0800